Rituximab + ACVBP regimen plus Pegfilgrastim
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated CD20-positive Large B-cell Lymphoma
Conditions
Untreated CD20-positive Large B-cell Lymphoma
Trial Timeline
May 1, 2004 → Jan 1, 2007
NCT ID
NCT00169143About Rituximab + ACVBP regimen plus Pegfilgrastim
Rituximab + ACVBP regimen plus Pegfilgrastim is a phase 2 stage product being developed by Amgen for Untreated CD20-positive Large B-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00169143. Target conditions include Untreated CD20-positive Large B-cell Lymphoma.
What happened to similar drugs?
1 of 4 similar drugs in Untreated CD20-positive Large B-cell Lymphoma were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00169143 | Phase 2 | Completed |
Competing Products
15 competing products in Untreated CD20-positive Large B-cell Lymphoma